The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
NextCell Pharma AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.78% SEK1.280
America/New_York / 17 mai 2024 @ 09:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.01 mill |
| EPS: | -1.150 |
| P/E: | -1.110 |
| Earnings Date: | N/A |
| SharesOutstanding: | 34.38 mill |
| Avg Daily Volume: | 0.0692 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.110 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -1.110 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.895 - 1.665 ( +/- 30.08%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK1.280 (-0.78% ) |
| Volume | 0.0564 mill |
| Avg. Vol. | 0.0692 mill |
| % of Avg. Vol | 81.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NXTCL.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NXTCL.ST
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.